Search PubMed⌕ Search

Biomedical subjects

D Zitnan

Publications and source records attributed to D Zitnan.

102 records · Page 6Linked to original sources
PubMedDate not supplied

[Systemic connective tissue diseases--prognostic conclusions of a 30-year study].

In the course of the last three decades a gradually supplemented group of 627 patients was subjected to prognostic analysis, incl. 388 with systemic lupus erythematosus, 160 with diffuse scleroderma, 51 with dermato- and polymyositis and 28 with a mixed connective tissue syndrome. Taking into account the onset of the disease, sex, extent of organ affection and therapy as well as the survival period and mortality, the conclusions of the statistical evaluation revealed that more than 90% of patients survived for more than 5 years: 92.2% with systemic lupus erythematosus, 94.3% with diffuse scleroderma 93.3% with dermato- and polymyositis and 100% with mixed connective tissue syndrome; a ten-year survival was recorded in cca 80% patients (77.6% with systemic lupus erythematosus, 81.1% with diffuse scleroderma, 89.7% with dermato- and polymyositis); a 15-year survival was recorded still by more than 50% patients (53.4% with systemic lupus erythematosus, 58.2% with diffuse scleroderma and as many as 80.0% with dermato- and polymyositis). The above data indicate considerable improvement of the prospects of these diseases, whereby the more than treble prolongation of survival of patients as compared with the previous period is due to effective, although not causal immunotherapy, in particular in systemic lupus erythematosus and dermato- and polymyositis.

Adult↗
PubMedDate not supplied

[Evaluation of Panergon therapy in Raynaud syndrome within the scope of progressive scleroderma].

In 15 patients with progressive systemic sclerosis with Raynaud's phenomenon Papaverin hydrochloride retard (Panergon) therapy was used. The average age of 14 females and 1 male was 42 years (26-55). Panergon therapy lasted for 4 weeks, the daily dose being 450 mg. For the evaluation of the treatment, 3 instrumental methods were used: IR radiometry for measuring thermal changes in the hands, capillaroscopy of nailfold, and Doppler-ultrasonic examination for measuring the circulation in finger arteries. An increased temperature, particularly in the fingertips, was found by radiometric examination in 6 patients. We also observed the acceleration of capillary flow speed in 7 patients. The pulse wave in finger arteries was markedly increased in 5 patients. From the subjective point of view the Panergon therapy was judged to be successful in 12 patients. It was not necessary to interrupt the treatment because of unfavourable effects in any case. Panergon therapy seems to be an important step in the treatment of Raynaud's phenomenon in progressive systemic sclerosis.

Adult↗
PubMedDate not supplied

Contribution to the problem of occurrence of tuberculosis in patients with systemic lupus erythematosus.

The association of SLE with tuberculosis (TB) was studied in a group of 388 patients with SLE monitored between 1953-1994. TB was diagnosed in 14 patients (3.6%). The occurrence of septic fevers in SLE patients that did not respond to glucocorticoid therapy indicated the possibility of complication with TB. SLE-associated TB included miliary and far-advanced pulmonary and extrapulmonary forms. Three patients from our group died due to myco-bacterial infection and one patient died of active SLE and TB. The treatment was successful in nine patients. Early diagnosis and appropriate management are mandatory in SLE associated TB, which otherwise may have a potentially fatal outcome.

Adolescent↗